title: A functional variant at miR-520a binding site in PIK3CA alters susceptibility to colorectal cancer in a Chinese Han population.
abstract: An increasing body of evidence has indicated that polymorphisms in the miRNA binding site of target gene can alter the ability of miRNAs to bind their target genes and modulate the risk of cancer. We aimed to investigate the association between a miR-520a binding site polymorphism rs141178472 in the PIK3CA 3'-UTR and the risk of colorectal cancer (CRC) in a Chinese Han population. The polymorphism rs141178472 was analyzed in a case-control study, including 386 CRC patients and 394 age- and sex-matched controls; the relationship between the polymorphism and the risk of colorectal cancer was examined. Individuals carrying the rs141178472 CC genotype or C allele had an increased risk of developing CRC (CC versus TT, OR (95% CI): 1.716 (1.084-2.716), P = 0.022; C versus T, OR (95% CI): 1.258 (1.021-1.551), P = 0.033). Furthermore, the expression of PIK3CA was detected in the peripheral blood mononucleated cell of CRC patients, suggesting that mRNA levels of PIK3CA might be associated with SNP rs141178472. These findings provide evidence that a miR-520a binding site polymorphism rs141178472 in the PIK3CA 3'-UTR may play a role in the etiology of CRC.
authors.affiliation: Department of Oncology, Danyang People's Hospital, Danyang 213000, China ; Department of Oncology, Affiliated Zhongda Hospital of Southeast University, Nanjing 210009, China.
authors.forename: Lifang
authors.initials: L
authors.lastname: Ding
authors.affiliation: Department of Oncology, Affiliated Zhongda Hospital of Southeast University, Nanjing 210009, China.
authors.forename: Zao
authors.initials: Z
authors.lastname: Jiang
authors.affiliation: Department of Central Laboratory, Affiliated People's Hospital of Jiangsu University, Zhenjiang 212002, China.
authors.forename: Qiaoyun
authors.initials: Q
authors.lastname: Chen
authors.affiliation: Department of Oncology, Affiliated People's Hospital of Jiangsu University, Zhenjiang 212002, China.
authors.forename: Rong
authors.initials: R
authors.lastname: Qin
authors.affiliation: Department of Central Laboratory, Affiliated People's Hospital of Jiangsu University, Zhenjiang 212002, China.
authors.forename: Yue
authors.initials: Y
authors.lastname: Fang
authors.affiliation: Department of Clinical Laboratory, Taixing People's Hospital, Taixing 225400, China.
authors.forename: Hao
authors.identifier: 0000-0002-5219-7234
authors.initials: H
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D001665:Binding Sites / Q000235:genetics*; D016022:Case-Control Studies; D002681:China; D058534:Class I Phosphatidylinositol 3-Kinases; D015179:Colorectal Neoplasms / Q000235:genetics* / Q000473:pathology; D005260:Female; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics; D012307:Risk Factors
chemical_list: C575048:MIRN520 microRNA, human; D035683:MicroRNAs; D012333:RNA, Messenger; D019869:Phosphatidylinositol 3-Kinases; D058534:Class I Phosphatidylinositol 3-Kinases; C484760:PIK3CA protein, human
references.citation: Int J Biochem Cell Biol. 2010 Aug;42(8):1273-81
references.pmid: 20026422
references.citation: Cancer Res. 2004 Nov 1;64(21):7678-81
references.pmid: 15520168
references.citation: Med Oncol. 2013;30(3):668
references.pmid: 23873015
references.citation: Neoplasma. 2015;62(1):72-80
references.pmid: 25563369
references.citation: Haematologica. 2014 Jan;99(1):7-18
references.pmid: 24425689
references.citation: Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1475-9
references.pmid: 16432179
references.citation: Tohoku J Exp Med. 2014;233(1):33-41
references.pmid: 24769516
references.citation: Jpn J Clin Oncol. 2010 Apr;40(4):281-5
references.pmid: 20085904
references.citation: Front Oncol. 2014 Mar 03;4:35
references.pmid: 24624362
references.citation: BMC Cancer. 2013;13:19
references.pmid: 23320911
references.citation: Cancer Res. 1998 Nov 15;58(22):5002-8
references.pmid: 9823298
references.citation: Science. 2007 Jul 13;317(5835):239-42
references.pmid: 17626883
references.citation: Carcinogenesis. 2011 Nov;32(11):1668-74
references.pmid: 21934093
references.citation: Cancer Res. 2010 Dec 1;70(23):9641-9
references.pmid: 21084273
references.citation: Dtsch Arztebl Int. 2010 Oct;107(43):760-6
references.pmid: 21085545
references.citation: Asian Pac J Cancer Prev. 2013;14(9):5117-22
references.pmid: 24175786
references.citation: Science. 2004 Apr 23;304(5670):554
references.pmid: 15016963
references.citation: PLoS One. 2013;8(6):e65479
references.pmid: 23785428
references.citation: Biochim Biophys Acta. 2010 Apr;1805(2):209-17
references.pmid: 19931352
references.citation: Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13653-8
references.pmid: 21810988
references.citation: Toxicol Appl Pharmacol. 2002 Nov 15;185(1):64-73
references.pmid: 12460738
references.citation: Appl Immunohistochem Mol Morphol. 2013 Mar;21(2):97-102
references.pmid: 23417071
references.citation: Clin Chim Acta. 2013 Feb 1;416:100-6
references.pmid: 23228846
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Arthritis Rheum. 2011 Mar;63(3):755-63
references.pmid: 21360505